Overview
- In a Phase 2b study with five-year follow-up, intismeran autogene plus Keytruda reduced the risk of recurrence or death by about 49% versus Keytruda alone.
- Moderna shares jumped roughly 16% to around $50, setting a new 52-week high following the data release.
- Moderna and Merck plan to share additional follow-up analyses of primary and secondary endpoints at an upcoming medical meeting.
- The Phase 3 adjuvant melanoma trial (INTerpath-001) is fully enrolled, while two Phase 3 NSCLC studies and multiple Phase 2 trials in renal and bladder cancers are enrolling.
- Analyst sentiment remains neutral despite the rally, with a consensus Hold rating and an average price target near $29.93.